BEIJING, January 18, 2022 /PRNewswire/ — InnoCare Pharma (HKEX:09969) and Keymed Biosciences (HKEX:02162) jointly announced today that the first patient of China was assayed in the clinical trial for CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for the treatment of CD20+ B-cell malignancies.
CM355 binds to CD20 on tumor cells and CD3 on T cells, redirects and activates T cells to eradicate tumor cells through T cell-directed cellular cytotoxicity (TDCC) in the treatment of malignant tumors with CD20+ B cells.
Non-Hodgkin’s lymphomas are the major type of CD20+ B-cell malignancies, accounting for 80%-90%, which include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and chronic disease. lymphoid leukemia/small lymphocytic lymphoma (CLL/SLL).
dr. Jasmine Cui, co-founder, president and CEO of InnoCare, said, “There is still a big gap in terms the 5-year survival rate of patients with lymphoma between China and Europe & WE. As two innovative biotechnology companies, we are working hard to develop more innovative medicines to address unmet clinical needs. We are fully convinced that the bispecific antibody CD20xCD3 has great potential in the clinical development of B-cell lymphoma.”
dr. Chen Bo, co-founder, president and CEO of Keymed Biosciences, said, “We are very pleased to have taken the first step in evaluating the potential clinical benefits of CM355 for lymphoma patients. Preclinical studies have shown the high potency and manageable safety of CM355. This means good treatment prospects for lymphoma patients. We look forward to working with InnoCare to efficiently conduct this clinical study and eventually provide more innovative, effective, safe and cost-effective treatment options for patients to prolong survival and improve prognosis.
About InnoCare
InnoCare is a commercial-stage biopharmaceutical company engaged in the discovery, development and commercialization of first-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphomas, solid tumors and autoimmune diseases with high unmet medical needs in China and around the world. InnoCare has branches in beijing, Nankeen, Shanghai, Canton, hong kong, New Jersey and Boston.
About Keymed Biosciences
Keymed Biosciences is a biotechnology company focused on the discovery and in-house development of innovative biological therapies in the autoimmune and oncology therapeutic areas. We have established a fully integrated platform encompassing all key biologic drug development functions, enabling us to quickly and cost-effectively identify, build, scale and advance our diverse pipeline. Keymed Biosciences has branches in Chengdu, beijing and Shanghai.
InnoCare Forward-Looking Statements
This report contains disclosure of certain forward-looking statements. Except for statements of fact, all other statements may be deemed to be forward-looking statements, that is, statements concerning our intentions, plans, beliefs or expectations or those of our management that will or may occur in the future. These statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future developments and other related factors. This forward-looking statement is not a guarantee of future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our performance in the short and long term.
Contact:
SOURCEInnocare
